Breast Cancer Clinical Trials in Houston, TX

Breast Cancer Clinical Trials in Houston, TX

View the best 10 breast cancer medical studies in Houston, Texas. Access promising new therapies by applying to a Houston-based Breast Cancer clinical trial.

Trials in Houston, Texas

Here are the top 10 medical studies for breast cancer in Houston, Texas

Image of Ironwood Cancer & Research Centers - Chandler II in Chandler, United States.

Trastuzumab deruxtecan (DS-8201a)

Monoclonal Antibodies

Recruiting2 awardsPhase 3
This trial will compare trastuzumab deruxtecan to other treatments for patients with HER2-low breast cancer that cannot be removed by surgery and has spread. The treatment targets and kills cancer cells by delivering chemotherapy directly to them. Trastuzumab deruxtecan has shown effectiveness in patients with HER2-low breast cancer, resulting in longer periods without the disease getting worse and longer life expectancy compared to other chemotherapy treatments.
Image of Houston Methodist Cancer Center in Houston, United States.

Olaparib +1 More

PARP Inhibitor

Recruiting3 awardsPhase 1
This trial is testing the safety and effectiveness of two drugs, olaparib and vorinostat, when used together to treat breast cancer that has returned or spread.
Image of Northwest Georgia Oncology Centers PC - Marietta in Marietta, United States.

Giredestrant +2 More

Selective Estrogen Receptor Degrader (SERD)

Recruiting1 awardPhase 2
This trial is testing giredestrant, a new drug, to see if it works better than usual hormone treatments for certain breast cancer patients. It targets patients whose cancer grows with the help of estrogen and who have already tried other treatments. The drug aims to block a protein that helps the cancer grow.
Image of Research Site in Mobile, United States.

AZD9833 +2 More

Selective Estrogen Receptor Degrader (SERD)

Recruiting1 awardPhase 3
This trial is comparing two drug combinations to treat a specific type of advanced breast cancer. One combination includes a new drug called camizestrant, and the other includes anastrozole. Both combinations also use palbociclib. The goal is to see which combination works better at slowing down the cancer.
Image of Northwestern Medicine Cancer Center in Warrenville, United States.

TOL2506

Hormone Therapy

Recruiting2 awardsPhase 3
This trial tests TOL2506, a treatment that stops ovaries from working, in premenopausal women and men with hormone-sensitive breast cancer. It aims to reduce hormone levels to slow down or stop cancer growth. TOL2506 is a treatment that stops ovaries from working, similar to other ovarian suppression methods.
Image of Pacific Cancer Care ( Site 0142) in Monterey, United States.

Olaparib +1 More

PARP Inhibitor

Recruiting1 awardPhase 2
This trial is comparing the efficacy of two different treatments for triple negative breast cancer - olaparib plus pembrolizumab versus chemotherapy plus pembrolizumab. The primary hypotheses are that olaparib plus pembrolizumab will be superior to chemotherapy plus pembrolizumab in terms of progression-free survival and overall survival.
Image of UC Irvine Health/Chao Family Comprehensive Cancer Center in Orange, United States.

Nab-paclitaxel +2 More

Chemotherapy

Recruiting1 awardPhase 2
This trial is testing how well a combination of chemotherapy drugs, immunotherapy drugs, and a personalized vaccine work in treating patients with metastatic triple negative breast cancer.
Image of Epic Care-Dublin in Dublin, United States.

Sacituzumab Govitecan

Monoclonal Antibodies

Recruiting1 awardPhase 2
This trial is studying sacituzumab govitecan to see how well it works in treating patients with HER2-negative breast cancer that has spread to the brain.
Image of University of Alabama at Birmingham Cancer Center in Birmingham, United States.

Radiation Therapy

Recruiting1 awardPhase 2
This trial is studying how well paclitaxel, trastuzumab, and pertuzumab work in eliminating chemotherapy after surgery in patients with HER2-positive stage II-IIIa breast cancer who have no cancer remaining at surgery.
Image of NRG Oncology-Pittsburgh Center in Pittsburgh, United States.

Tamoxifen +3 More

Hormone Therapy

Recruiting2 awardsPhase 3
This trial is testing whether a combination of surgery and hormone therapy is non-inferior to surgery, hormone therapy, and radiation for treating breast cancer.

Phase 3 Trials

Trials With No Placebo

View More Related Trials

Frequently Asked Questions

Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the 'trial drug' — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
Is there any support for travel costs?
Many of the teams running clinical trials will cover the cost of transportation to-and-from their care center.
Will I know what medication I am taking?
This depends on the specific study. If you're worried about receiving a placebo, you can actively filter out these trials using our search.
How long do clinical trials last?
Some trials will only require a single visit, while others will continue until your disease returns. It's fairly common for a trial to last somewhere between 1 and 6 months.
Do you verify all the trials on your website?
All of the trials listed on Power have been formally registered with the US Food and Drug Administration. Beyond this, some trials on Power have been formally 'verified' if the team behind the trial has completed an additional level of verification with our team.
How quickly will I hear back from a clinical trial?
Sadly, this response time can take anywhere from 6 hours to 2 weeks. We're working hard to speed up how quickly you hear back — in general, verified trials respond to patients within a few days.